EGFR+ Lung Cancer

>

Latest News

FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC

September 14th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.

Lower PFS Reported For EGFR-mutated Vs EGFR-wildtype NSCLC with Durvalumab
Lower PFS Reported For EGFR-mutated Vs EGFR-wildtype NSCLC with Durvalumab

September 11th 2023

Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC
Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC

September 10th 2023

Phase 2 Study of HER3-DXd Shows Promise in Advanced EGFR-Mutated NSCLC
Phase 2 Study of HER3-DXd Shows Promise in Advanced EGFR-Mutated NSCLC

September 10th 2023

Amivantamab Plus Chemo Extends PFS in Advanced EGFR-Mutated NSCLC
Amivantamab Plus Chemo Extends PFS in Advanced EGFR-Mutated NSCLC

September 6th 2023

Video Series
Video Interviews
Podcasts

More News